AGC Biologics Aims to Become ‘Safe Harbor’ for Manufacturing Clients as New CEO Takes the Reins

Emerging from the rough waters of the CDMO industry with a new chief executive at the helm, AGC Biologics is on a mission to reinvent itself as a manufacturing partner defined by friendliness and expertise at scale. After going through a series of layoffs this year, AGC appointed new CEO Alberto Santagostino at the top of the month, recruiting the CDMO expert off a six-year stint as head of cell and gene technology at Swiss manufacturing juggernaut Lonza.